The PCDC teams (also known as Units) are focused on developing and testing new molecular and imaging biomarkers to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions and identify individuals who are at high risk of developing PDAC and are candidates for early intervention. The eight PCDC teams are listed below. Principal Investigators are listed in alphabetical order by last name.
|Ajay Goel, Ph.D.
Daniel D. Von Hoff, M.D., F.A.C.P.
|Beckman Research Institute, City of Hope Comprehensive Cancer Center; Translational Genomics Research Institute
|Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
|Michael G. Goggins, Ph.D.
|Johns Hopkins University
|Using Markers to Improve Pancreatic Cancer Screening and Surveillance
|Michael (Tony) A. Hollingsworth, Ph.D.
|University of Nebraska Medical Center
|Pancreatic Cancer Detection Consortium – Biomarker Discovery and Validation
|Shounak Majumder, M.D.
|Mayo Clinic; University of Pennsylvania
|Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer
|Subrata Sen, Ph.D.
Ann Killary, Ph.D.
|The University of Texas MD Anderson Cancer Center
|Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer
|Julie L. Sutcliffe, Ph.D.
|University of California, Davis
|Peptide-based targeted molecular imaging for early detection in pancreatic cancer
|Andrei Iagaru, M.D.
Walter G. Park, M.D., M.S.
|Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma
|Brian M. Wolpin, M.D., M.P.H.
|Dana Farber Cancer Institute; Harvard Medical School
|Circulating Biomarker Consortium for Pancreatic Cancer Early Detection